Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bazedoxifene - Ligand Pharmaceuticals/Pfizer

Drug Profile

Bazedoxifene - Ligand Pharmaceuticals/Pfizer

Alternative Names: Bazedoxifene acetate; Bazedoxifeno; Brilence; Conbriza; TSE-424; Viviant; WAY 140424; WAY-TSE 424

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Developer Almirall S.A.; Ligand Pharmaceuticals; Pfizer
  • Class Azepines; Calcium regulators; Indoles; Osteoporosis therapies; Phenols; Small molecules
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Apr 2015 Bazedoxifene is still in Preregistration for Postmenopausal osteoporosis (Treatment and Prevention) in USA
  • 07 Apr 2015 Launched for Postmenopausal osteoporosis in Germany, Lithuania, Sweden, Croatia and Israel (PO) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top